Feed / ARCC

Ares Capital Corporation

ARCC

Financial Services · 19.11 -1.3% today

Partial group confirmationMarket checked 30 Sept, 15:55 GMT-4

Market read

Ares Capital Corporation's move is spreading beyond its market group.

ARCC accounts for 6.1% of the group's measured movement across 9.8 effective names. all 11 measured members are falling in raw terms, but 9 of 11 SPY-adjusted paths align to the downside. Capital-flow agreement is 9%, so confirmation is not yet clean. No verified headline preceded the measured group move.

MOVE ANATOMY

Is this move genuinely shared?

SPY-adjusted 5m paths
Role in the moveAligned contributor#9 of 11 by movement share
Group movement share6.1%Absolute path energy—not portfolio weight
Relative path-0.42%aligned
Effective breadth9.8 / 11broad
Relative alignment9/11downside path · 2 counter-moving
Capital-flow agreement9%not yet clean
SEQUENCE READ

OWL, FSK, OBDC moved materially before ARCC. ARCC crossed its material path threshold at 11:05 ET.

EVIDENCE COVERAGE

8 of 11 members in Biopharmaceuticals and Care are active. 0 of 5 disclosed connections are confirming.

What would change this read
  • At least 8 of 11 members remain active in the next snapshot.
  • Capital-flow agreement rises above 55%.
  • GSBD remains aligned with the group in the next market snapshot.

Invalidation: The live read weakens if participation falls to 3 of 11 members or fewer.

Watch this read

Research brief

The story so far

Financial Services · Asset Management

ARCC accounts for 6.1% of the group's measured movement across 9.8 effective names. all 11 measured members are falling in raw terms, but 9 of 11 SPY-adjusted paths align to the downside. Capital-flow agreement is 9%, so confirmation is not yet clean. No verified headline preceded the measured group move.

Evidence that supports

No thresholded supportive filing evidence is available yet.

Evidence that challenges

No thresholded adverse filing evidence is available yet.

What would clarify the read
  • At least 8 of 11 members remain active in the next snapshot.
  • Capital-flow agreement rises above 55%.
  • GSBD remains aligned with the group in the next market snapshot.

Company research

Understand the business, not just the ticker

As of Oct 1, 2026
Business model and earnings drivers

Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.

Key research questions
  • Which operating variable is changing?
  • Is that change durable, cyclical or one-off?
  • What evidence would disprove the current interpretation?
Annual periods0
Price observations341
Usable filing statements92
Verified relationships5
Evidence supporting the case
  • Credit and interest rates has repeated favorable evidence across 5 filings.
Evidence challenging the case

No qualifying adverse evidence was identified; that is not proof there is no downside.

Questions before a position

No credible peer-relative valuation comparison is available yet.

Longer-term price context

Price as of Sep 30, 2026

19.11
6m+6.0%12m-6.5%24m—

What management says matters

Persistent and emerging business drivers

Credit and interest ratespositive · 5 filings
“Stated interest expense for the three and six months ended June 30, 2026 increased from the comparable periods in 2025 primarily due to the increase in the average principal amount of our outstanding debt.”
10-Q · Jul 29, 2026 ↗
Macroeconomic conditionspositive · 1 filings
“These tailwinds were partially offset by increased uncertainty related to geopolitical developments, with markets now expecting the Federal Reserve to maintain policy rates at current levels this year amid rising near-term inflation expectations.”
10-Q · Apr 28, 2026 ↗
Tariffs and trade policypositive · 1 filings
“These tailwinds were partially offset by slower job growth and increased uncertainty related to tariff policies and risks from various geopolitical developments.”
10-K · Feb 4, 2026 ↗

Valuation discipline

Descriptive valuation snapshot

Price/sales — · EV/sales —. Comparisons use only industry-matched filing peers.

Scenario scaffold

Scenarios are withheld for Financial Services until sector-specific earnings and capital metrics are available; generic revenue/P/S scaffolds would be misleading.

Price action

How the market is pricing the story

19.11-1.3% today

Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 30 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.

Developments

No sourced recent-development timeline yet

Jodie has not returned a relevant primary source or news item for ARCC. This is an evidence-coverage gap, not a conclusion that nothing material happened.

Business and financial condition

Reported financial figures are not available yet

Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.

Filing analysis

No comparable filing assessment is available yet

Jodie has not yet found a suitable current-versus-prior filing comparison for ARCC. This does not mean the latest filing was neutral or immaterial.

Business ecosystem

The relationships behind ARCC

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depended on by

ADMAADMA Biologics, Inc.lenderFeb 25, 2026 ▾

“Ares Credit Agreement On December 18, 2023 (the “Ares Closing Date”), we entered into a senior secured credit facility (the “Ares Credit Agreement”) with Ares Capital Corporation and certain credit funds affiliated with Ares Capital Corporation (collectively,…”

Filing peers

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 4 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

ARCC is currently a Early Follower in the organic co-movement group Biopharmaceuticals and Care. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 1 filing-linked name are in the relationship map; none is currently confirmed as moving with the group.

Context history

Theme membership history

No durable theme membership has been observed for this name yet.